Blue Jet Healthcare Limited is set to significantly expand its manufacturing footprint with the establishment of a ₹23 billion greenfield pharmaceutical manufacturing facility at Rambilli Industrial Park. The 102-acre project is expected to strengthen India’s capabilities in contract development and manufacturing (CDMO) services and specialty pharmaceutical production.
Once operational, the facility will manufacture contrast media key intermediates, high-intensity sweeteners, and other versatile chemical products, enabling the company to expand its presence in both specialty chemicals and pharmaceutical intermediates. The project will be developed in phases and is expected to become operational by FY 2028–29.
Boost to Regional Economy and Employment
Beyond enhancing manufacturing capacity, the project is also expected to deliver significant economic benefits to the region. The investment is likely to further position the Visakhapatnam–Anakapalli corridor as an emerging hub for pharmaceutical manufacturing and specialty chemicals in India.
Growing Demand in the Contrast Media Market
The expansion aligns with rising global demand for contrast media intermediates used in diagnostic imaging. According to Precedence Research, the contrast media market was valued at $7.35 billion in 2025 and is projected to grow from $7.97 billion in 2026 to about $16.54 billion by 2035, registering a CAGR of 8.45% between 2026 and 2035.
The growth is being driven by increasing healthcare awareness, rapid technological advancements in medical imaging, and the rising prevalence of chronic diseases worldwide. Consequently, pharmaceutical companies are investing in advanced intermediates and reliable supply chains to meet expanding global demand.
From Jet Chemicals to a Global CDMO Player
Founded in 1968 as Jet Chemicals Pvt Ltd, the company later evolved into Blue Jet Healthcare Limited, building a strong reputation in pharmaceutical intermediates and active pharmaceutical ingredients (APIs).
The company operates as an integrated CDMO supplying advanced intermediates and APIs across India, Europe, and the United States. Notably, it has emerged as a key manufacturer of contrast media intermediates and was also among the early producers of Saccharin in India.
Over the years, Blue Jet Healthcare has strengthened its process chemistry expertise, scale-up capabilities, and regulatory-compliant manufacturing infrastructure, enabling it to serve leading global pharmaceutical companies.
Focus on Sustainability and ESG Compliance
Importantly, the upcoming Rambilli facility has been designed with strong sustainability and environmental compliance measures. The plant will incorporate zero liquid discharge (ZLD) technology and an advanced effluent treatment system connected to marine discharge infrastructure.
In addition, the company aims to reduce energy consumption by nearly 70% while recovering 90–95% of wastewater, aligning the project with stringent ESG benchmarks and environmental regulations within the pharmaceutical sector.
Leadership Driving Global Expansion
The expansion is being led by Akshay Bansarilal Arora and Shiven Akshay Arora, who are steering the company’s strategy to broaden its global CDMO footprint. The Rambilli investment reflects a broader industry shift, as multinational pharmaceutical companies increasingly seek diversified and resilient supply chains beyond single geographies. By expanding its manufacturing capacity and strengthening sustainable production capabilities, Blue Jet Healthcare aims to play a larger role in the global pharmaceutical value chain.
As reported by precedenceresearch.com, at the same time, the project is expected to enhance Rambilli Industrial Park’s status as a growing specialty chemicals and pharmaceutical manufacturing hub, supporting India’s ambition to become a major global supplier of complex pharmaceutical intermediates.
